#ScienceLink #TDXd #DESTINYBreast03

shorturl.at/EHZ45

#ScienceLink #TDXd #DESTINYBreast06
shorturl.at/acsN4

.VIRGINIA KAKLAMANI and Aditya Bardia, MD discussed the Phase III Destiny-Breast06 trial, in which TDXd demonstrated improvement in PFS in patients with HR-positive, HER2-low and HER2-ultralow metastatic breast cancer. Watch now on SABCS Snippets:
bit.ly/3JHpw9q
UT Health San Antonio MD Anderson

DB06 TDXD compared to chemo of choice showed positive PFS in MBC HR+ HER-2 low or ultralow post 1-2 line of endocrine therapy (Chemo-Naive Patients)
Sooo excited to see the Kaplan–Meier curves details #ASCO2024

News of the day! Press release from AstraZeneca; #Tdxd performs better in earlier lines in metastatic HR+ HER2 low and ultra-low. Definitely want to see the full data set, crossover etc. #bcsm OncoAlert

HR pos disease is rarely completely her2 0. There’s usually some her2 expression. Therefore results from this trial likely mean that we can use tdxd for all HR pos breast cancer. In TNBC things can be different since most of her2 0 tnbc has no her2 expression.

AZ reports DESTINYbreast06 trial which is first line study of TDXD vs chemo in her2 low or ultra low (i.e. 0) tumors. So essentially drug works irrespective of Her2 status and “HER2 low” is a thing of the past astrazeneca.com/media-centre/p…

A great thread by Paolo Tarantino of why using HER2 IHC testing to select patients for #tdxd may not be necessary. Awaiting the presentation/publication of DB-06! #bcsm #educatepatients #MedTwitter #MedX

astrazeneca.com/media-centre/p…

TDXdがHER2 ultra lowに効く現在でHER2調べる意義があるのかどうか議論されとる。
HER2 ultra lowってどんな定義なのか調べなきゃ。

In pts w/ HR+ mBC (with HER2low, or HER2 ultralow dz) TDXd led to a significant ⬆️ in PFS c/w TPC

Press release out from DESTINY-Breast06

Will be very interested to see the data; will have profound impact on tx sequencing + could put an end to HER2low as a biomarker

Really feel like we don't need to be testing for HER-2 for TDXd in #bcsm :
1) IHC testing isn't that good
2) HER-2 is so heterogeneous biopsy to biopsy
3) other ADCs we don't test (TROP, HER-3 etc). Only b/c it was 'HER-2' did we get stuck in this testing algorithm to begin with!

Seems like the gift that keeps giving! TDXD shows improvement in PFS in primary and overall population including HER2 low and HER2 ultra low HR + MBC in DESTINY-Breast06 Phase III trial. Can't wait to see the details ⁦OncoAlert⁩ #bcsm astrazeneca.com/media-centre/p…

ruru ^_~☆ hi

Paolo Tarantino Cancer Discovery Sara Tolaney G Curigliano MD PhD Biggest initial question is did HER 2 low patients in the chemo control arm get offered Tdxd on progression?

りさ はじめまして、フォローかdmおねがいします

TDXd effective also in HR+/HER2-ultralow MBC. Great news, but some questions arise: is there a minimal HER2 expression cut-off to define its activity? If yes, is IHC the best way to go for? How good is the benefit in Ultralow from safety and financial perspectives vs. SoC? (cont)

Harold J. Burstein, MD, PhD, FASCO Completely agree. HER2 is sufficient but not necessary for TDxD response. Unclear utility of further IHC di/trichotomization.

Fairytale Research Aren't you worried that the ex CEO and Chairwoman left without saying anything? Also there are lawsuits against them. It looks really undervalued but these are some important questions.

Y♡ はじめまして、こちらから行けなくてフォローかDMおねがいします

🌙 はじめまして、こちらから行けなくてフォローかDMおねがいします